Sartorius acquires Polyplus for $2.6B in cell and gene therapy expansion.

Sartorius is set to acquire French contract manufacturer Polyplus for $2.6 billion through its French subsidiary, Sartorius Stedim Biotech. Polyplus produces materials and components used in making viral vectors for cell and gene therapies. The deal is expected to close in Q3 2023 and Polyplus is expected to generate sales revenue in the "upper double-digit million-euro" range this year. This is not the first acquisition Sartorius has made in the cell and gene therapy space, having acquired UK-based Albumedix in 2022 and a 51% stake in CellGenix GmbH in 2021.